The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Open accessAbstract
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Heart Outcomes Prevention Evaluation 3 (HOPE-3), published in 2016, showed that low-dose statin therapy reduced the composite cardiovascular outcome by 24% but had no significant effect on mortality.19”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [621]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Flagged first, then by citations
Research works printed but not linked: 1
- Sackett DL, 2000, CMAJ, 162, 1311
Cited by
Sorted by citations
Items 401–500 of 847
Primary Prevention of Cardiovascular Disease in Asia: Opportunities and Solutions
Dalakoti, M., Lin, N. H. Y., Yap, J. J. L., Cader, F. A., Prajapati, D., Lee, D. P. H., Shariff, R. E. R., Cuenza, L. R., Honda, S., Malis, V., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101676 · Cited by 12
A Critical Appraisal of Lipid Management in the Post-Statin Era
Spitz, J. A., Patel, J., Agarwala, A., Sharma, G. V., Mehta, A., Natarajan, P., Nasir, K., Morris, P. B., Blumenthal, R. S., & Shapiro, M. D. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101823 · Cited by 12
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
Meireles-Brandão, J. A., Meireles-Brandão, L. R., Coelho, R. C., & Rocha‐Gonçalves, F. (2019) · Acta Médica Portuguesa · doi:10.20344/amp.10251 · Cited by 11
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 10
New insights in statins affecting atheromatous plaque macrophages
Härdtner, C., Ehlert, C. A., & Hilgendorf, I. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000769 · Cited by 10
Liu, T., Zuo, R., Wang, J., Huangtao, Z., Wang, B., Sun, L., Wang, S., Li, B., Zhu, Z., & Pan, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-31739-w · Cited by 10
Presta, V., Figliuzzi, I., Citoni, B., Miceli, F., Battistoni, A., Musumeci, B., Coluccia, R., Biase, L. D., Ferrucci, A., Volpe, M., et al. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13283 · Cited by 9
Pais, P. S., Jung, H. J., Dans, A., Zhu, J., Liu, L., Kamath, D. Y., Bosch, J., Lonn, E., & Yusuf, S. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318819019 · Cited by 10
Self-citationA Journey through Genetic Architecture and Predisposition of Coronary Artery Disease
Roberts, R., & Chang, C. C. (2020) · Current Genomics · doi:10.2174/1389202921999200630145241 · Cited by 10
Statin use and outcome risks according to predicted CVD risk in Korea: A retrospective cohort study
Jung, H. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245609 · Cited by 10
Self-citationEffect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
Yang, Y., Eun-Soon, H., Lee, S., Lee, S., Kim, D., Song, J., & Kang, D. (2021) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2020.0244 · Cited by 10
Time to improve statin prescription guidelines in low-risk patients?
Balder, J. W., de Vries, J. K., Mulder, D. J., & Kamphuisen, P. W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317698585 · Cited by 10
Does addressing prediabetes help to improve population health?
Mika Kivimaki, B., & Tabák, Á. G. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30030-5 · Cited by 10
Николаевна, Б. З., & Асланян, Н. С. (2017) · Systemic Hypertension · doi:10.26442/2075-082x_14.2.51-55 · Cited by 10
Enhancing the Operational Semantics of the Entity-Relationship Model.
Parent, C. E., & Spaccapietra, S. (1985) · Discovery Science · Cited by 10
Masson, W. M., Lobo, M., Barbagelata, L., & Nogueira, J. P. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02205-w · Cited by 9
Mazhar, F., Hjemdahl, P., Sjölander, A., Kahan, T., Jernberg, T., & Carrero, J. J. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.010 · Cited by 10
Bersch-Ferreira, Â. C., Stein, E., Waclawovsky, G., da Silva, L. R., Machado, R. H. V., Weschenfelder, C., Figueiró, M. F., Suzumura, É. A., Santos, R. H. N., Duarte, G. B. S., et al. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03455-2 · Cited by 9
Epigenetics is involved in the pleiotropic effects of statins
Filho, C. K. C., Pereira, V. C. R., Tavares, C. N., Pachado, M. P., Mónica, F. Z., Tanus-Santos, J. E., & Lacchini, R. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2491732 · Cited by 10
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Huesch, M. D. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.7844 · Cited by 9
Ogungbe, O., Grant, J. K., Ayoola, A., Bansah, E. C., Miller, H., Plante, T. B., Sheikhattari, P., Commodore-Mensah, Y. Y., Turkson‐Ocran, R., Juraschek, S. P., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01942-2 · Cited by 9
Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data
Mansi, I. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0190-3 · Cited by 9
New oral agents for treating dyslipidemia
Gryn, S. E., & Hegele, R. A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000354 · Cited by 9
Mortensen, M. B., Budoff, M. J., Li, D., Nasir, K., Blaha, M. J., Sandfort, V., Rodriguez, C. J., Ouyang, P., & Falk, E. (2017) · Circulation · doi:10.1161/circulationaha.117.029381 · Cited by 9
Jung, K. Y., Kim, K. M., Han, S. K., Yun, H. M., Oh, T. J., Choi, S. H., Park, K. S., Jang, H. C., & Lim, S. K. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0411 · Cited by 10
RetractedStatin consumption as a risk factor for developing colorectal cancer: a retrospective case study
Renman, D., Lundberg, E., Gunnarsson, U., & Strigård, K. (2017) · World Journal of Surgical Oncology · doi:10.1186/s12957-017-1287-0 · Cited by 9
Prediabetes in Colombia: Expert Consensus.
López-Jaramillo, P. A., Calderón, C., Castillo, J., Escobar, I. D., Enrique Melgarejo, R., & Parra, G. A. (2017) · Europe PMC (PubMed Central) · doi:10.25100/cm.v43i4.3662 · Cited by 9
Self-citationHow Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner
Cardoso, R. N., Blumenthal, R. S., Kopecky, S. L., López-Jiménez, F. A., & Martin, S. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.011 · Cited by 10
Stillman, M. D., & Williams, S. (2019) · Spinal Cord Series and Cases · doi:10.1038/s41394-019-0240-6 · Cited by 9
Kim, J., Hoang, T., Kim, J., Bu, S. Y., Choi, J., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 10
Pavlović, J., Greenland, P., Franco, O. H., Kavousi, M., Ikram, M. K., Deckers, J. W., Ikram, M. A., & Leening, M. J. G. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007183 · Cited by 9
Zinellu, A., & Mangoni, A. A. (2022) · Nitric Oxide · doi:10.1016/j.niox.2022.01.001 · Cited by 10
Ghouse, J., Ahlberg, G., Skov, A. G., Bundgaard, H., & OLESEN, M. S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025361 · Cited by 9
Polypill: Benefits Seen for Stroke and Other Outcomes
Brainin, M., Teuschl, Y., & Martins, S. C. O. (2022) · Stroke · doi:10.1161/strokeaha.122.037313 · Cited by 11
Blais, J. E., Ye, X., Wan, E. Y. F., Wong, W. C. W., Wong, I. C. K., Tomlinson, B., & Chan, E. W. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01208-9 · Cited by 9
Lipids and Women's Health: Recent Updates and Implications for Practice
Fay, K. E., Farina, L. A., Burks, H. R., Wild, R. A., & Stone, N. J. (2018) · Journal of Women s Health · doi:10.1089/jwh.2017.6745 · Cited by 12
Clearfield, M. B., Davis, G. E., Weis, J., Gayer, G. G., & Shubrook, J. H. (2018) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2018.157 · Cited by 10
High-Sensitivity Cardiac Troponin and Primary Prevention
Jaffe, A. S., & Wright, R. S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.006 · Cited by 9
Intensive blood pressure control on arterial stiffness among older patients with hypertension
Zhang, ., Zhong, Y., Wu, S., Wu, H., Cai, J., Zhang, W., & On behalf of the STEP Study Group (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002868 · Cited by 11
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Accounting for center-level effects in multicenter randomized controlled trials
Islam, S., & Bangdiwala, S. I. (2024) · Trials · doi:10.1186/s13063-024-08202-w · Cited by 10
Xu, H., Ma, Y., Xu, L.-L., Li, Y., Liu, Y., Li, Y., Zhou, S., Zhou, W., Lee, S., Zhang, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56669-1 · Cited by 8
Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation
Sgarra, L., Desantis, V., Matteucci, A., Caccavo, V. P., Troisi, F., Monaco, A. D., Mangini, F., Katsouras, G., Guaricci, A. I., Dadamo, M. L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030660 · Cited by 9
Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review
Tam, F. C.-C., Lin, M.-G., Lam, T.-H., Tse, H.-F., & Wong, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1659228 · Cited by 16
Lipid metabolic alterations in cancer: Common pathophysiology with cardiovascular disease
Llena-Meler, M., Canfrán‐Duque, A., Madrigal‐Matute, J., & Rotllán, N. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.003 · Cited by 12
Collister, D., Rodrigues, J. C., Mbuagbaw, L. C. E., Devereaux, P. J., Guyatt, G. H., Herrington, W. G., & Walsh, M. W. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.09.035 · Cited by 8
Volpe, M., & Patrono, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab647 · Cited by 8
Long-term statin use and risk of cancers: a target trial emulation study
Xu, W., Chan, L. S., Danaei, G., Lu, Y., & Wan, E. Y. F. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111425 · Cited by 8
Wang, Y., Kuang, Z.-M., Feng, S., Jiang, L., Chen, Q., Ji, X., Cheng, W., & Hu, H. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019719 · Cited by 8
Management of dyslipidaemias in the elderly population—A narrative review
Anagnostis, P. G., Vaitsi, K., Veneti, S., Georgiou, T., Paschou, S. Α., Lambrinoudaki, I. V., & Goulis, D. G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.03.011 · Cited by 8
Cardiovascular Health and Healthy Aging
Reynolds, I. J., Page, R. L., II, & Boxer, R. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-06200-2_5 · Cited by 10
Second revolution in cardiovascular prevention
Chiang, C., Wang, K.-L., Cheng, H., Sung, S., & Chao, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000276 · Cited by 8
Esperança, E. S., Bonatto, M. S., da Costa, M. C., Meirelles, A. J. A., & Máximo, G. J. (2022) · Fluid Phase Equilibria · doi:10.1016/j.fluid.2022.113432 · Cited by 9
Pinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.001 · Cited by 8
Noh, J. H., Moon, M. K., Rhee, E., Park, S. H., Kim, H. C., Kim, B. J., Kim, H. J., Choi, S., Na, J. O., Hyun, Y. Y., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0320 · Cited by 8
Fiore, V., Barucca, A., Barraco, S., Triggiani, D., Tragni, D., Piazzolla, G., Triggiani, V., Carbotta, G., & Lisco, G. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230428092828 · Cited by 8
Statins do not Increase the Rate of Bleeding Among Warfarin Users
Korhonen, M. J., Tiittanen, P., Kastarinen, H., Helin‐Salmivaara, A., Hauta‐aho, M., Rikala, M., & Huupponen, R. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12998 · Cited by 8
Yebyo, H. G., Aschmann, H. E., Menges, D., Boyd, C. M., & Puhan, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319877745 · Cited by 9
Statins and Diabetes: Current Perspectives and Implications for Clinicians
Hennekens, C. H., Teng, B., & Pfeffer, M. A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.12.022 · Cited by 8
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 7
Nie, F., Wang, Z., Zeng, Q., Guan, H., Yang, J., Luo, P., Du, L., Wang, J., & Hong, F. (2021) · BMC Public Health · doi:10.1186/s12889-021-10871-0 · Cited by 7
Ohwada, T., Sakamoto, T., Suzuki, S., Sugawara, Y., Sakamoto, K., Ikeda, A., Haga, F., Sato, T., Nakazato, K., Takeishi, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18914-1 · Cited by 7
Mehta, A., Dixon, D. L., Saeed, A., Kelly, M. S., Gulati, M., Shapiro, M. D., Sperling, L. S., & Virani, S. S. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01861-2 · Cited by 7
Kuang, Y., Li, X., Chen, X., Sun, H., Tomlinson, B., Chan, P., Zheng, L., Pi, J., Peng, S., Wu, H., et al. (2016) · Scientific Reports · doi:10.1038/srep34268 · Cited by 7
The epidemic of cardiovascular disease in South Asians: Time for action
Yusuf, S., & Joseph, P. G. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.11.009 · Cited by 6
Self-citationRabaeus, M., Nguyen, P., & de Lorgeril, M. (2017) · Journal of Controversies in Biomedical Research · doi:10.15586/jcbmr.2017.18 · Cited by 7
Coenzyme Q10 supplementation in the management of statin-associated myalgia
Tan, J. T., & Barry, A. R. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160714 · Cited by 7
Risk-Benefit Assessment of Carotid Revascularization
de Oliveira, P. P., Vieira, J. L. D. C., Guimarães, R. B., Almeida, E. D., Savaris, S. L., & Portal, V. L. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180208 · Cited by 7
Mortensen, M. B., & Nordestgaard, B. G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.12.002 · Cited by 7
A systematic review and meta-analysis of the effect of statin treatment on sVCAM-1 and sICAM-1
Zinellu, A., & Mangoni, A. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2072294 · Cited by 7
Cholesterol Treatment Trialists’ Collaboration (2022) · Clinical Trials · doi:10.1177/17407745221105509 · Cited by 7
Statin therapy for the primary prevention of cardiovascular disease: Cons
Durai, V., & Redberg, R. F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.003 · Cited by 7
A stepwise approach to prescribing novel lipid-lowering medications
Kakavand, H., Aghakouchakzadeh, M., Shahi, A., Virani, S. S., Dixon, D. L., Tassell, B. W. V., & Talasaz, A. H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.003 · Cited by 7
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
Grützmacher, P., Öhm, B., Szymczak, S., Dorbath, C., Brzoska, M., & Kleinert, C. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0090-3 · Cited by 7
Hashikata, T., Tojo, T., Muramatsu, Y., Sato, T., Kakizaki, R., Nemoto, T., Fujiyoshi, K., Namba, S., Kitasato, L., Hashimoto, T., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39560 · Cited by 7
Statines en prévention primaire des événements cardiovasculaires
Adham, S., Miranda, S., Doucet, J., Levesque, H., & Benhamou, Y. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.08.002 · Cited by 7
Guijarro, C., & Camafort, M. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.05.010 · Cited by 8
Cataracts and statins. A disproportionality analysis using data from VigiBase
Saint-Gerons, D. M., Cortez, F. B., López, G. J., Castro, J. L., & Tabarés‐Seisdedos, R. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104509 · Cited by 7
Schwalm, J.-D., McCready, T., Lear, S. A., Lamelas, P. M., Garis, L., Musa, H., Vincent, K., Islam, S., Attaran, A., McKee, M., et al. (2020) · CJC Open · doi:10.1016/j.cjco.2020.10.006 · Cited by 7
Self-citationLeong, D. P., Rangarajan, S., Rosengren, A., Oğuz, A., AlHabib, K. F., Poirier, P., Díaz, R., Dans, A. L., Iqbal, R., Yusufali, A., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac069 · Cited by 7
Self-citationGoyal, A., Cooper, H. A., Aronow, W. S., Nagpal, P., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.05.029 · Cited by 6
Wang, Y., Courcelles, E., Peyronnet, E., Porte, S., Diatchenko, A., Jacob, E., Angoulvant, D., Amarenco, P., Boccara, F., Cariou, B., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01557-7 · Cited by 9
Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction
Yaghoubi, D., & Sallam, T. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.07.002 · Cited by 6
The fibrinolytic system in disease: From molecular pathways to clinical outcomes
Alibrahim, M. N., Sahli, K. A., & Alshehri, F. S. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109504 · Cited by 9
Banach, M., Toth, P. P., Ahn, H., Bielecka-Dabrowa, A. M., Cicero, A. F. G., Covic, A. C., Dalakoti, M., Escobar, C., Fogacci, F., Gaiță, D. I., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.003 · Cited by 8
Lee, C. J., Kang, W. C., Ihm, S., Sohn, I. S., Woo, J. S., Kim, J. W., Hong, S. J., Choi, J. H., Suh, J., Seo, J., et al. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14778 · Cited by 5
Bolt, L., Speierer, A., Bétrisey, S., Aeschbacher‐Germann, M., Blum, M. R., Gencer, B., Giovane, C. D., Aujseky, D., Moutzouri, E., & Rodondi, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297852 · Cited by 6
Statins for the primary prevention of venous thromboembolism
Wang, Z., Zhang, P., Tian, J., Zhang, P., Yang, K., & Li, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014769.pub2 · Cited by 6
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 9
Ung, L., VanderWeele, T. J., & Dahabreh, I. J. (2025) · Epidemiology · doi:10.1097/ede.0000000000001863 · Cited by 6
Statin myopathy: navigating the maze
Rizos, C. V., & Elisaf, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1255601 · Cited by 6
The Global Perspective of Ischemic Heart Disease
Lawlor, M. K., Gersh, B. J., Opie, L. H., & Gaziano, T. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00002-9 · Cited by 6
Yamazaki, K., Takahashi, Y., Teduka, K., Nakayama, T., Nishida, Y., & Asai, S. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0314-x · Cited by 6
Hussain, A., Rifai, M. A., Mahtta, D., Liu, J., Jain, V., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00900-5 · Cited by 6
Olesen, K. K. W., Heide‐Jørgensen, U., Thim, T., Thomsen, R. W., Bøtker, H. E., Sørensen, H. T., & Mæng, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab040 · Cited by 6
Iyer, T. K., & Hirsch, H. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21031 · Cited by 6
A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study
Hong, J. H., Jeon, U., Shin, W., Kim, W., Seong, K., Park, S., Kim, H., Chung, J., & Choi, J.-H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.004 · Cited by 6
Tohidi, M., Asgari, S., Chary, A., Azizi, F., & Hadaegh, F. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.08.007 · Cited by 6
Tobita, K., Takahara, M., Iida, O., Soga, Y., Yamaoka, T., Ichihashi, S., & Saito, S. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63874 · Cited by 6
Metadata
- Authors
- Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., Avezum, A., Piegas, L. S., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R. J. G., Held, C., Chazova, I., Yusoff, K., Lewis, B. S., Jansky, P., Khunti, K., Toff, W. D., Reid, C. M., Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., & Lonn, E.
- Affiliations
- St. Michael's Hospital (CA)
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- Yusuf, Salim
- Bosch, Jackie
- Dagenais, Gilles
- Zhu, Jun
- Xavier, Denis
- Liu, Lisheng
- Pais, Prem
- López-Jaramillo, Patricio
- Leiter, Lawrence A.
- Piegas, Leopoldo S.
- Parkhomenko, Alexander
- Keltai, Katalin
- Sliwa, Karen
- Peters, Ron J.G.
- Held, Claes
- Chazova, Irina
- Yusoff, Khalid
- Lewis, Basil S.
- Khunti, Kamlesh
- Toff, William D.
- Reid, Christopher M.
- McKelvie, Robert
- Jung, Hyejung
- Lonn, Eva
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2021-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313998826
- Cited by
- 848
- References
- 23
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 61 · 2023: 66 · 2022: 84 · 2021: 90 · 2020: 75 · 2019: 109 · 2018: 101 · 2017: 97 · 2016: 78
- FWCI
- 142.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Canadian Institutes of Health Research (IR2-91038))
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- rosuvastatin, statins, cholesterol lowering, intermediate cardiovascular risk, primary prevention, cardiovascular events, LDL cholesterol, ethnic diversity, C-reactive protein, cataract surgery, statin adverse effects, muscle symptoms, diabetes risk, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization, cardiac arrest, cardiovascular risk stratification, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
